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Abstract
Introduction: Haemostatic therapy in surgical and/or massive trauma patients typically involves transfusion of fresh
frozen plasma (FFP). Purified human fibrinogen concentrate may offer an alternative to FFP in some instances. In
this systematic review, we investigated the current evidence for the use of FFP and fibrinogen concentrate in the
perioperative or massive trauma setting.
Methods: Studies reporting the outcome (blood loss, transfusion requirement, length of stay, survival and plasma
fibrinogen level) of FFP or fibrinogen concentrate administration to patients in a perioperative or massive trauma
setting were identified in electronic databases (1995 to 2010). Studies were included regardless of type, patient
age, sample size or duration of patient follow-up. Studies of patients with congenital clotting factor deficiencies or
other haematological disorders were excluded. Studies were assessed for eligibility, and data were extracted and
tabulated.
Results: Ninety-one eligible studies (70 FFP and 21 fibrinogen concentrate) reported outcomes of interest. Few
were high-quality prospective studies. Evidence for the efficacy of FFP was inconsistent across all assessed
outcomes. Overall, FFP showed a positive effect for 28% of outcomes and a negative effect for 22% of outcomes.
There was limited evidence that FFP reduced mortality: 50% of outcomes associated FFP with reduced mortality
(typically trauma and/or massive bleeding), and 20% were associated with increased mortality (typically surgical
and/or nonmassive bleeding). Five studies reported the outcome of fibrinogen concentrate versus a comparator.
The evidence was consistently positive (70% of all outcomes), with no negative effects reported (0% of all
outcomes). Fibrinogen concentrate was compared directly with FFP in three high-quality studies and was found to
be superior for > 50% of outcomes in terms of reducing blood loss, allogeneic transfusion requirements, length of
intensive care unit and hospital stay and increasing plasma fibrinogen levels. We found no fibrinogen concentrate
comparator studies in patients with haemorrhage due to massive trauma, although efficacy across all assessed
outcomes was reported in a number of noncomparator trauma studies.
Conclusions: The weight of evidence does not appear to support the clinical effectiveness of FFP for surgical and/
or massive trauma patients and suggests it can be detrimental. Perioperatively, fibrinogen concentrate was
generally associated with improved outcome measures, although more high-quality, prospective studies are
required before any definitive conclusions can be drawn.
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Surgery and massive trauma are frequently associated
with significant derangement of haemostatic capacity
caused by loss, consumption, endogenous inhibition (by
the protein C pathway), dilution of coagulation factors
(termed ‘dilutional coagulopathy’ or ‘acute coagulopathy
of shock and trauma’) and increased clot breakdown
(fibrinolysis). Most commonly, haemostatic therapy in
patients without preexisting haemostatic disorders aims
to substitute key components (clotting factors and other
blood components) by transfusion of allogeneic blood
products, including fresh frozen plasma (FFP), platelet
concentrate (PC), packed red blood cells (RBC) and, in
some countries, cryoprecipitate.
Clinical use of FFP in component therapy has
increased over the past four decades [1]. Reports of the
success of high FFP:RBC ratios may be responsible for
some of this rise [2-4]. The benefits of any intervention
should outweigh the risks. FFP has been associated with
increased risk of morbidity and mortality [5,6], whilst
the evidence to support the effectiveness of FFP in the
perioperative setting or its appropriate dosing in the
massive transfusion setting has been questioned [7-10].
Fibrinogen is a key protein in the new ‘cell-based’
model of haemostasis that involves four consecutive
overlapping stages (initiation, amplification, propagation
and stabilisation), in which the conversion of fibrinogen
to a covalently linked fibrin network is the final stage
[11,12]. Of note, fibrinogen is the first coagulation factor
to fall to a suboptimal level early during bleeding and
dilutional coagulopathy [13]. Fibrinogen supplementa-
tion is therefore recommended in patients with massive
bleeding to maintain plasma fibrinogen levels above 1.5
to 2.0 g/L [14]. Supplementation of fibrinogen may be
most effective when performed as part of early goal-
directed coagulation management [15]. Typically, stan-
dard preparation FFP contains 2.0 g/L (range = 0.9 to
3.2 g/L) fibrinogen (equivalent to 0.6 g in a 300-ml
unit), as well as other pro- and anticoagulant factors
found in plasma, acute phase proteins (cytokines), elec-
trolytes, immunoglobulins and albumin [9,16]. Fibrino-
gen concentrate (from various manufacturers) is
currently licensed for use in congenital bleeding in
C h i n a ,J a p a n ,t h eU S Aa n dt h r o u g h o u tE u r o p e ,a n df o r
use in acquired bleeding in > 15 countries globally. Pas-
teurised and lyophilised human fibrinogen concentrate
is typically reconstituted in 50 ml of sterile water to a
final concentration of 20 g/L. Each vial of fibrinogen
concentrate contains 1.0 g (range = 0.9 to 1.3 g) of fibri-
nogen, as well as albumin, L-arginine hydrochloride,
sodium chloride and sodium citrate [17]. The concen-
trated dose of fibrinogen provided by fibrinogen concen-
trate (final concentration 10 times higher than FFP)
might be preferable to FFP for restoring plasma fibrino-
gen levels because of its rapid availability (no thawing),
reduced volume (faster infusion time) and increased
safety, and it has recently been suggested to be more
effective than administration of FFP [15]. However,
despite growing evidence based on both preclinical and
clinical studies to support its efficacy and safety [17-20],
fibrinogen concentrate is not yet a standard component
of many transfusion protocols.
This systematic review was performed to investigate
the evidence base for the use of FFP and fibrinogen con-
centrate in the perioperative and/or massive trauma set-
ting. We have included observational studies and case
series in addition to randomised, controlled trials
(RCTs) to provide a comprehensive overview of the cur-
rent clinical situation.
Materials and methods
Study concept and administrative structure
The initial rationale behind this systematic review was
formulated by the lead author (SKL), who subsequently
recruited the coauthors, arranged for an unrestricted
educational grant from CSL Behring (Marburg, Ger-
many), a manufacturer of fibrinogen concentrate, and
liaised closely with Fishawack Communications (Oxford,
UK), which provided editorial support. Within this
structure, we had full control of the ideas, data, report-
ing and conclusions of the research and were not influ-
enced by any commercial activities. Our study did not
require ethical approval.
Search criteria
Studies reporting the administration of FFP or fibrino-
gen concentrate in a perioperative or massive trauma
setting were identified in MEDLINE and EMBASE (1
January 1995 to 31 December 2010). The reference lists
of identified studies and relevant reviews were checked
for additional citations and to identify key FFP RCTs
conducted prior to 1995.
In the electronic database search, we used ‘periopera-
tive’, ‘surgery’, ‘h(a)emostasis’, ‘bleeding’, ‘traumatic inju-
ries’, ‘blood component transfusion’ as both input words
and subject headings. The FFP search also included
‘fresh frozen plasma’, ‘FFP’, ‘plasma’ and ‘therapeutic
plasma’, and the fibrinogen concentrate search com-
prised ‘fibrinogen/therapeutic use’, ‘fibrinogen concen-
trate’, ‘fibrinogen concentrates’. Additional limits were
added: (1) language: English or German; (2) date range:
1 January 1995 to 31 December 2010; and (3) article
type: clinical trial, meta-analysis, RCTrandomized con-
trolled trial, case reports, clinical trial phases I to IV,
comparative study, controlled clinical trial and journal
article. Titles and abstracts were screened for relevance,
Kozek-Langenecker et al. Critical Care 2011, 15:R239
http://ccforum.com/content/15/5/R239
Page 2 of 25and full publications of the potentially relevant studies
were assessed against the formal eligibility criteria.
Eligibility criteria
Studies were eligible for inclusion in the systematic
review if they reported a predefined outcome of the
administration of FFP or fibrinogen concentrate specifi-
cally within the perioperative or massive trauma setting.
All preparations of FFP (’standard’ as well as ‘pathogen-
reduced’) were eligible for inclusion. Abstracts of work
presented at congresses were excluded.
Outcomes of interest included blood loss, allogeneic
transfusion requirements, survival, hospital and/or ICU
length of stay (LOS), plasma fibrinogen levels, thrombo-
tic events, acute lung injury (ALI), transfusion-associated
circulatory overload (TACO), infections (bacterial con-
tamination and viral transmission) and multiple organ
failure (MOF). A meta-analysis of the effect of FFP on
morbidity was recently published by Murad and collea-
gues [5]. To avoid redundancy, outcomes related to
morbidity (thrombotic events, ALI, TACO, infections
[bacterial contamination and viral transmission] and
MOF) were not extracted and tabulated for FFP studies.
All study types were included (RCTs, non-RCTs, pro-
spective comparator studies, retrospective comparator
studies, prospective and retrospective noncomparator
studies, and case reports). Study design and quality of
evidence were captured at the data extraction stage.
Studies were included regardless of patient age, sample
size or duration of patient follow-up. We excluded pre-
clinical studies, studies which included patients with
congenital clotting factor deficiencies or other haemato-
logical disorders and studies reporting the prophylactic
administration of FFP or fibrinogen concentrate in the
absence of surgery. Studies reporting mixed populations
were included only if > 50% of the cases were surgical
and/or trauma patients. Studies reporting the adminis-
tration of FFP for liver disease or reversal of vitamin K
anticoagulation were excluded if there was no surgical
intervention. Studies in which control groups received
autologous platelet-rich plasma were also excluded. For
assessment of the effect of each intervention on survival,
studies that reported no deaths in either study arm were
excluded from the survival outcome but included in all
other applicable outcomes of interest.
Data extraction
Data from eligible studies were extracted according to
the population, intervention, comparison and outcome
(PICO) method into a standard form and included study
size, study type, number of study arms (including the
presence of a control group), the number and age (pae-
diatric or adult) of patients in each arm, indication for
and nature of the intervention (including the control
group where applicable), the presence of chronic liver
disease, treatment with anticoagulants, methods for
measuring (where applicable) blood loss and fibrinogen
levels, and relevant outcome data. Where possible,
blood loss and transfusion requirements were recorded
as intra-, peri- or postoperative (where perioperative was
the intra- and postoperative periods combined), and sur-
vival rates were recorded by the time period reported (6
hours, 24 hours, 30 days, in-hospital, and so on). Conse-
quently, in some instances, multiple outcomes from a
single study were included.
Analysis
Studies were categorised by type, then assessed by the
effect of the intervention on each applicable outcome
criterion. Each intervention (FFP or fibrinogen concen-
trate) could show a positive, negative or null effect
against the comparator group or against absolute values
where no comparator group was available. As such, data
from the observational and case studies were generally
descriptive in nature and were only included as suppor-
tive evidence. Studies without comparator groups were
not included in any formal calculations of the efficacy of
the intervention. Where outcome measures were com-
pared between groups within a study, these comparisons
were assessed on the basis of a difference in group
averages (mean or median as available). The primary
purpose of this review was achieved by describing the
numbers and the quality of studies identified in relation
to the effect of FFP or fibrinogen concentrate on the
stated outcome measures. To avoid redundancy and the
inclusion of multiple instances of data from the same
study, meta-analyses were not intended to be formally
included in the analysis (that is, outcomes from meta-
analyses were not counted towards the number of stu-
dies reporting the effect of an intervention for each out-
come). Instead, meta-analyses were included
descriptively as supportive evidence. Meta-analysis was
not a stated aim of this review, and analysis of the data
extracted from the eligible trials formed the basis of the
conclusions reached.
Results
Studies included
The selection process and study flow are depicted in
Figure 1. The majority of identified citations were easily
excluded at the level of title or abstract on the basis of
no relevance to this review. After screening, there were
91 studies that fulfilled our eligibility criteria, reported
outcomes of interest and were formally included in the
analysis (Tables 1, 2 and 3). There was also one meta-
analysis that was used as supportive evidence. Only a
minority of selected studies (n = 18) were high-quality
prospective studies with randomisation procedures and
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and observational studies with a comparator group were
included. The majority (62%) of FFP studies involved
the comparison of the intervention group against a dif-
ferent dosage (typically by assessing the effect of differ-
ent FFP:RBC ratios), formulation (various kinds of
‘pathogen-reduced’ plasmas) or blood product (for
example, cryoprecipitate or whole blood). There were
only 20 studies in which FFP was compared with no
FFP or with a non blood product (for example, colloid
or crystalloid). There were five fibrinogen concentrate
comparator studies, two comparing fibrinogen concen-
trate with no fibrinogen concentrate or with a non
blood product and, importantly, three studies comparing
the effect of fibrinogen concentrate directly with FFP
(administered in combination with other allogeneic
products).
The average amount of FFP administered in each
study varied greatly, ranging from a nominal prophylac-
tic dose to tens of units (typically in the massive transfu-
sion studies). Several studies did not report the FFP
dose administered. The dosage of fibrinogen concentrate
typically ranged from 2 to 8 g. In studies of massive
transfusion, the intervention group was classified as
those patients receiving the highest FFP:RBC ratio (typi-
cally 1:1), whereas the control groups comprised those
patients who received lower FFP:RBC ratios. Control
groups from studies in which the effect of FFP:RBC
ratios was not assessed typically received various forms
of colloid or crystalloid, apart from those studies directly
comparing the administration of fibrinogen concentrate
with that of FFP (in addition to other allogeneic
components).
Articles and studies excluded because of overlapping and
duplicate data
Studies containing overlapping or duplicate populations
were excluded prior to the completion of the data
tables. Two articles reported the same data comparing
the outcomes of liver transplant patients who were
administered either standard FFP or solvent/detergent-
treated FFP (SD-FFP) [21,22]. Data from the more
recent publication were used [22]. The same study of
infants undergoing craniofacial surgery was published in
3953 records identified 
through database  searching
9 additional records identified 
through other sources
2673 records screened (after 
duplicates removed)
2487 records excluded after 
screening title/abstract
186 records selected for full 
text screening
95 excluded after full text 
screening:
• 7 Not original research
• 55 Outcomes of interest 
not reported
• 14 With <50% surgical/ 
massive trauma patients
• 19 Intervention  not relevant
91 studies included in 
systematic review
Figure 1 Study flowchart.
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Study Indication Study
type
N patients
(intervention
group vs
controls)
Intervention details Control group
FFP
Boyd et al.
(1996) [108]
Surgery (renal
transplantation; renal
disease and
coagulopathy)
RCT 39 (19 vs 20) FFP 2 U Conjugated oestrogen 50 mg
Chong Sung
et al. (2006)
[35]
CV surgery (paediatric) RCT 42 (21 vs 21) FFP 10 ml/kg HES (130/0.4) 10 ml/kg
Consten
et al.
(1996) [36]
CV surgery RCT 50 (24 vs 26) FFP 3 U Plasma substitute 3 U
Demeyere et
al. (2010)
[37]
CV surgery in patients on
OAT
RCT 40 (20 vs 18) FFP 4 U (additional doses
could be administered to
reach target INR)
PCC calculated to target INR of 1.5
(additional doses could be administered
to reach target INR)
Etemadrezaie
et al. (2007)
[78]
Traumatic brain injury RCT 90 (44 vs 46) FFP 10 to 15 ml/kg Saline 10 to 15 ml/kg
Haubelt
et al.
(2002) [38]
CV surgery Block-
RCT
67 (31 vs 36) FFP 600 ml SD-FFP 600 ml
Kasper et al.
(2001) [41]
CV surgery RCT 56 (27 vs 29) FFP 15 ml/kg 6% HES (450/0.7) 15 ml/kg
Laine et al.
(2003) [64]
Liver transplantation RCT 33 (15 vs 18) FFP median 14 U (+10 U
RBC)
WB median 12 U
Menges
et al.
(1992) [43]
Surgery (other) RCT 42 (16 vs 12/14) (Autologous) FFP + blood
(dose not reported)
Homologous RBC/autologous blood
(dose not reported)
Mintz et al.
(2006) [65]
Liver transplantation RCT 51 (29 vs 22) FFP 22.7 U over 7 days PCT-FFP 21.3 U over 7 days
Noddeland
et al. (2002)
[45]
CV surgery RCT 84 (55 vs 29) SD-FFP (2:1 Uniplas:Octaplas)
median 3 U Uniplas:2 U
Octaplas
No FFP
Trimble et al.
(1964) [48]
CV surgery (adults,
children)
RCT 53 (21 vs 32) FFP 2 U adults, 1 U children No FFP
von
Sommoggy
et al. (1990)
[49]
Surgery (other) RCT 24 (13 vs 11) FFP (+ human albumin)
mean 2.7 U
HES (dose not reported)
Wilhelmi
et al.
(2001) [50]
CV surgery Block-
RCT
120 (60 vs 60) FFP 4 U (1,000 ml) HES 1,000 ml
Williamson
et al.
(1999) [22]
(duplicate
data
in [21])
Surgery (liver) RCT 25 (13 vs 12) FFP median 44 ml/kg SD-FFP median 44 ml/kg
Fibrinogen concentrate
Cui et al.
(2010) [56]
CV surgery (children) RCT 31 (17 vs 14) Fibrinogen concentrate 0.5
to 1.0 g
’Standard allogeneic therapy’
Fenger-
Eriksen et al.
(2009) [71]
Surgery (cystectomy) RCT 20 (10 vs 10) Fibrinogen concentrate 45
mg/kg
Placebo (isotonic saline) 2.25 ml/kg
Karlsson
et al.
(2009) [54]
CV surgery RCT 20 (10 vs 10) Fibrinogen concentrate 2 g No fibrinogen concentrate
CV = cardiovascular; FFP = fresh frozen plasma; HES = hydroxyethyl starch; INR = International Normalised Ratio; OAT: oral anticoagulant therapy; PCT-FFP:
photochemical treatment fresh frozen plasma; PCC: prothrombin complex concentrate; RBC: packed red blood cells; RCT = randomised, controlled trial; SD-FFP =
solvent/detergent-treated fresh frozen plasma; WB = whole blood.
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Study Indication Study type N (intervention
group vs
controls)
Intervention details Control group
FFP
Antolovic et al.
(2008) [75]
Surgery (ischaemic
colitis)
Retrospective
comparator
81 (30 vs 51) FFP ≥ 3 U FFP < 3 U
Apaydin et al.
(2002) [76]
CV surgery Retrospective
comparator
85 (16 vs 69) FFP > 2 U FFP ≤ 2U
Bochicchio et al.
(2008) [77]
Trauma Prospective
comparator
922 FFP mean 5.4 U No FFP
Borgman et al.
(2007) [34]
Massive trauma Retrospective
comparator
246 FFP:RBC high 1:1.4 FFP:RBC 1:2.5 and 1:8
Chowdhury et al.
(2004) [109]
Various Prospective
comparator
22 (10 vs 12) FFP standard dose
median 12.2 ml/kg
FFP high dose median
33.5 ml/kg
Dente et al.
(2009) [30]
Massive trauma Prospective cohort vs
historical control
157 (73 vs 84) FFP:RBC ≥ 1:2 (MTP) FFP:RBC < 1:2 (pre MTP)
Duchesne et al.
(2008/2009/2010)
[31-33]
Massive trauma, surgery
(TIC), trauma
Retrospective
comparator
385/135/196 FFP:RBC 1:1 Ratios outside 1:1
Gunter (2008)
et al. [28]
Massive trauma Prospective cohort vs
historical control
259 (64 vs 195) FFP:RBC 1:1 to 1:1.5 FFP:RBC < 1:1.5 and > 1:1
Hildebrandt
(2007)
et al. [23] and
Kerner et al.
(2008) [24]
Surgery (craniofacial,
infants)
Non RCT 30 (15 vs 15) FFP mean 45 ml/kg 5% human albumin
Holcomb et al.
(2008) [3]
Massive trauma Retrospective
comparator
466 FFP:RBC ≥ 1:2 FFP:RBC < 1:2
Inaba et al.
(2010) [79]
Trauma (nonmassive
transfusion)
Retrospective
matched cohort
568 (284 vs 284) FFP mean 3.0 U No FFP
Johansson et al.
(2007) [39]
CV surgery Prospective cohort vs
historical control
148 (55 vs 93) FFP:RBC 1:1 (transfusion
package) mean 10 U
FFP:RBC < 1:1 (pre
transfusion package)
mean 7 U
Johansson et al.
(2009) [69]
Surgery (various) with
massive transfusion
Prospective cohort vs
historical control
832 (442 vs 390) FFP:RBC 1:1.3 (transfusion
package)
FFP:RBC 1:1.6 (pre
transfusion package)
Kaibori et al.
(2008) [40]
Surgery (hepatectomy for
hepatocellular carcinoma)
Retrospective
comparator
184 (43 vs 141) FFP median 4.0 U No FFP
Kashuk et al.
(2008) [80]
Massive trauma Retrospective
comparator
133 FFP:RBC 1:1 FFP:RBC 1:2, 1:3, 1:4 or
1:5
Koch et al. (2009)
[105]
CV surgery Retrospective
matched cohort
1928 (964 vs 964) FFP, dose not reported No FFP
Maegele et al.
(2008) [81]
Massive trauma Retrospective
comparator
713 FFP:RBC 1:1 FFP:RBC < 0.9:1 and >
1.1:1
Massicotte et al.
(2005) [82]
Liver transplantation Retrospective
comparator
66 (26 vs 40) FFP mean 4.9 U No FFP
Mell et al. (2010)
[42]
CV surgery Retrospective
comparator
128 (87 vs 41) FFP:RBC ≥ 1:2 FFP:RBC < 1:2
Miller et al.
(1997)
[44]
CV surgery (paediatric) Prospective
comparator
36 (19 vs 17) FFP, dose not reported Cryoprecipitate, dose not
reported
Mitra et al. (2010)
[66]
Massive trauma Retrospective
comparator
331 FFP:RBC > 1:1.5 FFP:RBC < 1:1.5
Oberkofler et al.
(2010) [83]
Liver transplantation Retrospective
comparator
144 FFP > 10 U FFP < 10 U
Ono et al. (2002)
[84]
CV surgery Retrospective
comparator
60 (39 vs 21) FFP 3.2 U No FFP
Reed et al. (1986)
[46]
Trauma Prospective cohort vs
published data
40 (16 vs 24) FFP 2 U/12 U blood No FFP
Riskin et al.
(2009) [85]
Massive trauma Retrospective
comparator
77 FFP:RBC 1:1.8 (MTP) FFP:RBC 1:1.8 (pre MTP)
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reported in both articles, the earlier publication was
used [23]. Two articles also reported data from the
same trial of patients undergoing cardiovascular (CV)
surgery [25,26]. The article reporting the greater num-
ber of outcomes of interest was retained [26].
Three massive transfusion studies reported data from
an overlapping population [2,27,28]; however, two of
these publications compared cohorts of patients pre-
and postimplementation of a massive transfusion proto-
col. The publication that specifically compared different
FFP:RBC ratios was used in this review [28]. Overlap-
ping data were reported in another three massive trans-
fusion studies [4,29,30]. One reported the results from
the first year of a prospective study assessing the effect
of the FFP:RBC ratio on survival and compared these
with matched historical cases [30], the second reported
the results from the entire prospective study only [29]
and the entire prospective data set was analysed against
matched historical cases in the third [4]. Survival data
were taken from the most recent publication in which
the entire prospective data set was compared against
matched historical cases [4]. Additional outcomes of
interest were found in the earliest publication, so they
were included where appropriate [30]. There were over-
lapping populations in another three massive transfusion
publications [31-33]. For the purposes of this review,
they were classified as a single study because subsets of
patients were analysed in each publication.
Blood loss
Fresh frozen plasma
Of the comparator studies reporting the effect of FFP on
blood loss, one reported lower blood loss as a result of
FFP [34]. The investigators in this massive trauma study
compared high, medium and low FFP:RBC ratios.
Patients receiving a high ratio (1:1.4) of FFP:RBC were
less likely than patients in the low ratio group to have
uncontrolled early haemorrhage (1:8).
In total, 18 of 20 outcomes indicated no reduction in
blood loss (primarily reported as postoperative blood
loss) for the FFP group in relation to the comparator
Table 2 Summary details of eligible comparator trials (Continued)
Rose et al. (2009)
[86]
Massive trauma Retrospective
comparator
204 FFP:RBC 1:1 FFP:RBC < 0.9:1 and >
1.1:1
Roy et al. (1988)
[47]
CV surgery Retrospective
comparator
(sequential cohorts)
100 (52 vs 48) FFP mean 5.8 U 5% albumin
Scalea et al.
(2008)
[87]
Trauma Prospective
comparator
250 FFP:RBC 1:1 Ratios outside 1:1
Scheele et al.
(2001) [88]
Surgery (liver resection
for colorectal metastases)
Retrospective
comparator
425 (159 vs 308) FFP, dose not reported No FFP
Shaz et al. (2010)
[4]
Massive trauma Retrospective
comparator
214 FFP:RBC ≥ 1:2 FFP:RBC < 1:2
Snyder et al.
(2009) [89]
Massive trauma Retrospective
comparator
134 (60 vs 74) FFP:RBC ≥ 1:2 FFP:RBC < 1:2
Sperry et al.
(2008) [67]
Massive trauma Retrospective
comparator
415 FFP:RBC ≥ 1:1.5 FFP:RBC < 1:1.5
Stinger et al.
(2008) [90]
Massive trauma Retrospective
comparator
252 FFP high fibrinogen:RBC
> 0.2 g fibrinogen/1 U
RBC)
FFP low fibrinogen:RBC <
0.2 g fibrinogen/1 U RBC)
Teixeira et al.
(2009) [91]
Massive trauma Retrospective
comparator
383 FFP:RBC > 1:2 FFP:RBC < 1:8, 1:8 to 1:3
and 1:3 to 1:2
Tomimaru et al.
(2010) [92]
Surgery (hepatectomy for
hepatocellular carcinoma)
Retrospective
comparator
497 (204 vs 293) FFP median 10 U No FFP (in 93% of
patients in the group)
Wright et al.
(2008)
[93]
CV surgery Retrospective
comparator
211 (129 vs 82) FFP (mixed donors)
median 6 U
FFP (male-only donors)
median 4 U
Zink et al. (2009)
[68]
Massive trauma Retrospective
comparator
466 FFP:RBC ≥ 1:1 FFP:RBC < 1:1
Fibrinogen concentrate
Rahe-Meyer et al.
(2009) [55]
CV surgery Non RCT 15 (10 vs 5) Fibrinogen concentrate
mean 5.7 g
FFP mean 4.2 U
Rahe-Meyer et al.
(2009) [26]
CV surgery Prospective cohort vs
historical control
18 (6 vs 12) Fibrinogen concentrate
mean 7.2 g
FFP mean 9.1 U
CV = cardiovascular; FFP = fresh frozen plasma; MTP = massive transfusion protocol; RBC = packed red blood cells; RCT = randomised, controlled trial; TIC =
trauma-induced coagulopathy.
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Study Indication Study type Patients
(N)
Intervention details Control
group
FFP
Aiyagari et al. (2005)
[51]
Trauma (gunshot injury) Case report 3 FFP 10 U, 4 U, 8 U No control
group
Dann et al. (2008)
[110]
Massive trauma Retrospective
noncomparator
21 FFP:RBC 1:1.5 No control
group
Díaz-Gómez et al.
(2010) [94]
CV surgery Retrospective
noncomparator
14,868 FFP No control
group
Fan et al. (2003) [95] Liver transplantation Prospective
noncomparator
100 FFP No control
group
Fischer et al. (2008)
[52]
GI bleeding (preterms) Retrospective
noncomparator
5 FFP 10 to 30 ml/kg/30 minutes No control
group
Gonzalez et al. (2007)
[96]
Massive trauma Retrospective
noncomparator
97 FFP mean 5 U No control
group
Lei et al. (2009) [106] CV surgery Retrospective
noncomparator
298 FFP mean 1,090 ml No control
group
Magner et al. (2007)
[111]
Liver transplantation Case report 2 SD-FFP 42 U, 16 U No control
group
Moore et al. (2008)
[97]
Massive trauma Prospective
noncomparator
93 FFP 6.3 U No control
group
Pull ter Gunne et al.
(2010)
[107]
Surgery (other) Retrospective
noncomparator
300 FFP mean 2.61 U No control
group
Ranucci et al. (2008)
[98]
CV surgery Retrospective
noncomparator
4546 FFP No control
group
Schols et al. (2008)
[53]
Surgery (CV, abdominal or spinal
bone)
Prospective
noncomparator
51 FFP mean 780 ml No control
group
Spinella et al. (2008)
[99]
Trauma Retrospective
noncomparator
708 FFP mean 3 U No control
group
Stricker et al. (2010)
[70]
Surgery (other, paediatric) Retrospective
noncomparator
159 FFP mean 20 ml/kg No control
group
Swisher et al. (1996)
[100]
Surgery (oesophageal resection
for cancer)
Retrospective
noncomparator
275 FFP No control
group
Tenza et al. (2009)
[101]
Liver transplantation Retrospective
noncomparator
74 FFP mean 15.7 U No control
group
Watson et al. (2009)
[103]
Trauma Retrospective
noncomparator
842 FFP median 4.8 U No control
group
Wiederkehr et al.
(2010) [102]
Liver transplantation Retrospective
noncomparator
155 FFP No control
group
Fibrinogen concentrate
Bell et al. (2010) [112] Postpartum haemorrhage Case series 6 Fibrinogen concentrate No control
group
Böhrer (1999) [57] Liver transplantation Case report 1 Fibrinogen concentrate 2 g No control
group
Brenni et al. (2010)
[58]
Trauma Case report 1 Fibrinogen concentrate 16 g No control
group
Farriols Danés et al.
(2008)
[104]
Various Retrospective
noncomparator
69 Fibrinogen concentrate median
4g
No control
group
Fenger-Eriksen et al.
(2008)
[59]
Severe bleeding Retrospective
noncomparator
43 Fibrinogen concentrate mean
2.0 g
No control
group
Glover et al. (2010)
[63]
Postpartum haemorrhage Case report 1 Fibrinogen concentrate No control
group
Haas et al. (2008)
[113]
Surgery (craniofacial, paediatric) Case series 9 Fibrinogen concentrate median
76 mg/kg
No control
group
Heindl et al. (2005)
[116]
Surgery (other) Case report 2 Fibrinogen concentrate 7 g, 8 g No control
group
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Page 8 of 25group [23,35-50] (Table 5). In one study, 2 of 52
patients who received FFP had ‘significant bleeding’ >
1,100 ml) versus 0 of 48 in the group that received 5%
albumin, though there was no significant difference
between the groups in mean blood loss [47]. In another
study, the researchers reported a (nonsignificant) trend
towards increased chest tube drainage (CTD) in the FFP
group compared with the control group that received
prothrombin complex concentrates [37]. In addition, in
one study of paediatric cardiopulmonary bypass surgery
patients, patients who weighed > 8 kg showed signifi-
cantly greater 24-hour CTD volume following adminis-
tration of FFP than those who did not receive FFP [44].
All three noncomparator trials that were identified
reported no reduction in blood loss following administra-
tion of FFP [51-53]. Two studies, one block-RCT [38]
(evaluating the effectiveness of FFP versus ‘pathogen-
reduced’ plasma) and one prospective observational study
[53], showed mixed results following administration of
FFP. In the RCT, the efficacy of FFP was reported as
‘good’ (defined as the infusion causing arrest or > 50%
reduction in CTD within a six-hour period) in 42% of
patients; however, it was judged to have had no influence
on the amount of blood lost in 23% of patients [38]. There
was no significant difference between the FFP and ‘patho-
gen-reduced’ plasma groups. In the observational study,
37% of patients continued to bleed after FFP administra-
tion [53]. Interestingly, the plasma fibrinogen level, as well
as its increase, after transfusion was markedly lower in
patients with ongoing bleeding than in those who stopped
bleeding, suggesting that the amount of fibrinogen deliv-
ered by the administration of FFP (mean ± SD = 780 ±
280 ml) was not sufficient to achieve haemostasis in a sub-
set of patients.
Fibrinogen concentrate
Four comparator studies reported the effect of fibrino-
gen concentrate on blood loss (Table 5). Three of these
studies involved adults, of which one was an RCT
Table 3 Summary details of eligible noncomparator trials (Continued)
Innerhofer (2006) [60] Surgery (lumbar) Case report 1 Fibrinogen concentrate 5 g No control
group
Peitsidou et al. (2008)
[114]
Emergency caesarean section
and
Hysterectomy
Case report 1 Fibrinogen concentrate 2 g No control
group
Schöchl et al. (2010)
[61]
Massive trauma, then laparotomy Case report 1 Fibrinogen concentrate 13 g No control
group
Schöchl et al. (2010)
[62]
Trauma surgery Case report 1 Fibrinogen concentrate 12 g No control
group
Schöchl et al. (2010)
[73]
Trauma surgery Retrospective
noncomparator
128 Fibrinogen concentrate median
7g
No control
group
Solomon et al. (2010)
[72]
CV surgery Retrospective
noncomparator
39 Fibrinogen concentrate mean
6.5 g
No control
group
Thorarinsdottir et al.
(2010)
[74]
Surgery (various) Retrospective
noncomparator
37 Fibrinogen concentrate median
2g
No control
group
Weinkove et al. (2008)
[115]
Various Retrospective
noncomparator
30 Fibrinogen concentrate median
4g
No control
group
Other
Murad et al. (2010) [5] Various Meta-analysis 12,421 FFP Various
CV = cardiovascular; FFP = fresh frozen plasma; GI = gastrointestinal; SD-FFP = solvent/detergent-treated fresh frozen plasma.
Table 4 Summary of included studies
Study types and interventions FFP, n (%) Fibrinogen concentrate, n (%)
Study type N =7 0 N =2 1
RCT 15 (21.4%) 3 (14.3%)
Comparator study 37 (52.9%) 2 (9.5%)
Noncomparator study 18 (25.7%) 16 (76.2%)
Comparison group intervention N =5 2 N =5
Colloid, crystalloid or no intervention 20 (38%) 2 (40%)
Alternative dosage or formulation 32 (62%) 0 (0%)
Fibrinogen concentrate vs FFP Included in adjacent column 3 (60%)
Meta-analysis N =1 N =0
FFP = fresh frozen plasma; RCT = randomised, controlled trial.
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Page 9 of 25involving the prophylactic administration of 2 g of fibri-
nogen concentrate prior to surgery [54]. The other two
were comparator trials evaluating the post cardiopul-
monary bypass administration of 7.8 ± 2.7 g [55] and
5.7 ± 0.9 g [26] fibrinogen concentrate compared with
approximately 8 U of FFP (+PC) in patients with
ongoing bleeding. All three studies showed a positive
effect of fibrinogen concentrate administration, which
reduced postoperative blood loss by 32 to 59% com-
pared with the control group, which received ‘standard’
allogeneic transfusion therapy in two cases [26,54,55].
Another RCT investigated the effect of fibrinogen con-
centrate administration and transfusion therapy guided
by thromboelastography compared with ‘standard allo-
geneic transfusion therapy’ in children undergoing com-
plex CV surgery [56]. Postoperative blood loss at 1, 6
and 24 hours by CTD was similar in both groups.
Researchers in another seven noncomparator articles
(one retrospective observational study and six case stu-
dies) observed a beneficial effect of fibrinogen concen-
trate on blood loss, with haemostasis frequently
achieved after allogeneic transfusion therapies had failed
[57-63]. The retrospective observational study of 43
patients (comprising 39 adults, 8 of whom were
excluded from analysis because of early death, and 4
newborns) reported a significant decrease in median
blood loss (from 4,000 to 50 ml) in the adult patients
following administration of fibrinogen concentrate dur-
ing serious haemorrhage [59]. A case report of a trauma
patient suggested that 15 U of FFP would have been
required to achieve haemostasis in place of the 5-g fibri-
nogen concentrate administered, which would have
exposed the patient to the risk of volume overload as
well as the risks associated with administration of any
allogeneic blood product [60].
Allogeneic transfusion requirements
Fresh frozen plasma
A total of 19 comparator studies reported 22 outcomes
of the effect of FFP on allogeneic transfusion require-
ments [22,23,30,35-37,39,41,43,44,47,49,50,64-69]. These
requirements were reported as intraoperative, postopera-
tive or total (studies in which the requirements were
reported for the whole perioperative period). Of these
studies, only five showed some benefit for FFP over the
comparator group, with the majority of the studies find-
ing no effect and two studies reporting an increase in
allogeneic transfusion requirements in the groups
receiving FFP (Table 6).
Seven studies investigated the effect of FFP compared
with a non blood product (for example, colloid and/or
crystalloid). Six of these showed no difference in the
Table 5 Evidence for the effect of each intervention on blood loss
FFP outcomes: blood loss Fibrinogen concentrate outcomes:
blood loss
Study type Reduction No difference Increase Reduction No difference Increase
RCT - 2 (intraoperative)
[43,45]
9 (postoperative)
[35-38,41,45,48-50]
-1
(postoperative)
[54]
1
(postoperative)
[56]
-
Non RCT or prospective comparator - 2 (postoperative)
[23,44]
1
(postoperative)
[44]
1
(postoperative)
[55]
--
Retrospective comparator 1
(perioperative)
[34]
2 (intraoperative)
[39,40]
2 (postoperative)
[46,47]
1 (perioperative)
[42]
-1
(postoperative)
[26]
--
Controlled and/or comparator study outcomes, n
(percentage of all outcomes within intervention
group)
1 (5%) 18 (90%) 1 (5%) 3 (75%) 1 (25%) 0
Prospective noncomparator - 1 (postoperative)
[53]
----
Retrospective noncomparator - 1 (postoperative)
[52]
-1
(perioperative)
[59]
--
Case report - 1 (perioperative)
[51]
-6
(perioperative)
[57,58,60-63]
--
Study outcomes, n (percentage of outcomes
within intervention group)
1 (4%) 21 (92%) 1 (4%) 10 (91%) 1 (9%) 0
FFP = fresh frozen plasma; RCT = randomised, controlled trial; - = no data.
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Page 10 of 25intraoperative [23], postoperative [23,35,36,47] or total
[41,49] requirements (requirements were measured as
either RBC or any allogeneic product and excluded the
study dose of FFP). A block-RCT of coronary artery bypass
graft surgery patients compared those who received 4 U of
FFP intraoperatively with controls who received hydro-
xyethyl starch (HES) [50]. The study showed that transfu-
sion requirements for RBC were significantly higher (both
intra- and postoperatively) among those patients receiving
FFP compared with patients administered HES. A further
(paediatric) study also found that a greater proportion of
patients in the FFP group required postoperative transfu-
sions compared with those not receiving FFP [44]. Two
studies that compared FFP with ‘pathogen-reduced’
plasma showed no differences between groups in the total
requirements for allogeneic transfusion [22,65].
There were six articles in which the effect of the FFP:
RBC ratio on transfusion requirements was assessed.
Three found reduced RBC requirements at higher FFP:
RBC ratios (typically 1:1 to 1:1.5) [66-68]. At FFP:RBC
ratios ≥ 1:2 versus < 1:2, there was no difference in RBC
requirements over the initial 6 or 24 hours; however,
the longer-term > 24 hours) transfusion requirements
for both RBC and FFP were lower in the higher ratio
group [30]. One further study (of low sample size) also
demonstrated that postoperative RBC, FFP and PC
requirements were reduced by increasing the amount of
FFP administered intraoperatively to achieve a FFP:RBC
ratio closer to 1:1 [39].
There were another two noncomparator studies (one
prospective and one retrospective) reporting the effect of
FFP on allogeneic transfusion requirements [53,70]. The
volume of intraoperatively transfused FFP was inversely
associated with the postoperative administration of allo-
geneic products in one (paediatric) study [70]. There was
a mixed response to FFP in the other study; 2 U were
Table 6 Evidence for the effect of each intervention on allogeneic transfusions
FFP outcomes: allogeneic transfusions Fibrinogen concentrate outcomes:
allogeneic transfusions
Type of study Reduction No difference Increase Reduction No difference Increase
RCT - 3 (postoperative)
[35-37]
6 (perioperative)
[22,41,43,49,64,65]
1 (intraoperative)
[50]; 1
(postoperative)
[50]
2
(postoperative)
[56,71]
2
(intraoperative)
[56,71]
1
(postoperative)
[54]
-
Non RCT or prospective comparator - 1 (intraoperative)
[23]
1 (postoperative)
[23]
1 (postoperative)
[44]
1
(postoperative)
[55]
--
Retrospective comparator 1
(postoperative)
[39]
1 > 24 hours
postoperative)
[30]
3 (total) [66-68]
1 (postoperative)
[47]
2 ≤ 24 hours
postoperative)
[30,69]
-1
(intraoperative)
[26]
1
(postoperative)
[26]
--
Controlled and/or comparator study
outcomes, n (percentage of all outcomes
within intervention group)
5 (23%) 14 (63%) 3 (14%) 5 (63%) 3 (37%) 0
Prospective noncomparator - 1 (postoperative)
[53]
- ---
Retrospective noncomparator 1
(postoperative)
[70]
-- 2
(intraoperative)
[72,73]
3
(postoperative)
[59,72,74]
1
(perioperative)
[73]
--
Case report - - - 5
(perioperative)
[57,58,60-62]
--
Study outcomes (percentage of outcomes, n
(within intervention group)
6 (25%) 15 (63%) 3 (12%) 16 (84%) 3 (16%) 0
FFP = fresh frozen plasma; RCT = randomised, controlled trial; - = no data. Allogeneic products are defined as any combination of packed red blood cells,F F P ,
platelets and/or cryoprecipitate.
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Page 11 of 25sufficient to achieve haemostasis in 63% of patients, while
the remaining 37% received additional transfusions [53].
Fibrinogen concentrate
The effect of fibrinogen concentrate on allogeneic trans-
fusions was assessed in five comparator trials, four of
which showed a reduction in requirements as a result of
the intervention [26,54-56,71] (Table 6). Notably, the
exposure to all allogeneic products (RBCs, FFP and PC)
transfused postoperatively was reduced in two of these
studies [26,55]. In the control groups (treated with
approximately 8 U of FFP), 100% of patients received
postoperative transfusions compared with only 20% [55]
and 44% [26] of patients who received fibrinogen concen-
trate. A third study reported lower postoperative RBC
requirements in the fibrinogen concentrate group com-
pared with the control group (that received saline), with
no difference found for intraoperative RBC requirements
[71]. The fourth study, a RCT of children undergoing CV
surgery, found a significant reduction in postoperative
and total FFP requirements in the fibrinogen concentrate
group compared with the control group [56]. The inter-
vention group received less than half the amount of FFP
than the control group (10.6 ± 6.5 ml/kg versus 22.5 ±
13.1 ml/kg). No differences were seen in the amount of
intra-, post- or perioperative RBC administered. A fifth
study reported no difference in the amount of postopera-
tive allogeneic products administered to the group that
had received a prophylactic dose of 2 g of fibrinogen con-
centrate prior to surgery compared with the control
group (no fibrinogen concentrate) [54].
Four retrospective noncomparator studies provided
evidence for a reduction in allogeneic transfusion
requirements following administration of fibrinogen
concentrate, with a further five case studies also suggest-
ing a reduction as a result of the intervention
[57-62,72-74]. One of the noncomparator studies that
presented data derived from CV surgery patients
reported that 35 of 39 patients did not receive any
further intraoperative FFP or PC after administration of
fibrinogen concentrate (the remaining four patients
received PC) [72]. In addition, in the postoperative per-
iod, only 11 of 39 patients required additional transfu-
sions, whereas in another sizable study of trauma
patients, only 6 of the 123 patients who received fibrino-
gen concentrate were administered intraoperative FFP,
and only 12 of 128 received FFP in the first 24 hours
after admission to the emergency room [73]. The other
two noncomparator studies demonstrated a reduction in
allogeneic transfusions, with one reporting a drop in
transfusion of RBC from 6 U to 3 U after administration
of fibrinogen concentrate [74] and the other reporting
significantly fewer allogeneic transfusions in the 24
hours after administration of the fibrinogen concentrate
than in the 24 hours prior to administration [59].
Survival
Fresh frozen plasma
We found 32 comparator studies involving FFP report-
ing results from 40 time points over periods ranging
from 6 hours to 10 years [3,4,28,31-34,38-40,42,
66-69,75-93] (Table 7). Eight studies compared the
effect of FFP with no FFP, of which, three showed no
effect of the intervention on survival (trauma with non-
massive transfusion [79], hepatectomy for hepatocellular
carcinoma [40] and CV surgery [84]), and five reported
reduced survival for patients receiving FFP (trauma [77],
traumatic brain injury [78], liver transplantation [82],
liver resection for colorectal metastases [88] and hepa-
tectomy for hepatocellular carcinoma [92]). In the
trauma study, the investigators found a dose-dependent
correlation between FFP transfusion and mortality, with
each unit of FFP given increasing the risk of death by
3.5% [77].
The effect of FFP on patient mortality has largely been
reported in the form of articles exploring the impact of
different FFP:RBC ratios, of which we found 19 such
studies. Sixteen studies reported the impact of FFP:RBC
ratios in trauma patients, typically by comparing a pro-
spective cohort that received a ‘transfusion protocol’
with a historical cohort that received treatment prior to
implementation of the protocol [3,4,28,31-34,66-68,
80,81,85-87,89-91]. In general, outcomes were favour-
able for patients who received more FFP than for those
who received less FFP, though the exact ratio needed to
achieve an improvement in the survival rate was not
consistent. In fact, one study suggested that the survival
rate followed a U-shaped curve and that the lowest pre-
dicted mortality was associated with a FFP:RBC ratio of
1:2 to 1:3, with a FFP:RBC ratio of 1:1 resulting in
reduced survival [80].
Murad and colleagues [5] conducted a meta-analysis
of studies reporting of the effect of FFP on mortality
compared with a control group and found that, for
patients undergoing massive transfusion > 10 U of
RBC), FFP:RBC ratios in the range of 1:2.5 to 1:1 were
associated with a significant reduction in mortality risk
(OR = 0.38). However, this improvement in survival was
reversed in surgical patients who did not receive massive
transfusions, where FFP was associated with a trend
towards increased mortality (OR = 1.22).
Ten noncomparator studies also reported on the effect
of FFP on survival [94-103]. Both studies of CV surgery
patients showed a significant association between FFP
and reduced in-hospital survival (OR = 2.51 and OR =
12.6) [94,98]. In one trauma study, FFP was shown to
have no effect on mortality when early deaths < 48
hours) were excluded. Furthermore, FFP administration
was associated with a 2.9% decreased risk of mortality
for every unit transfused when the early deaths were
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Page 12 of 25included [103]. Higher levels of FFP were also reported
to improve survival in two trauma studies [97,99].
Another study found no significant association between
FFP administered in the ICU and in-hospital survival
rates (OR = 1.03) [96].
Fibrinogen concentrate
Only three fibrinogen concentrate studies, one retro-
spective comparator study and two retrospective non-
comparator studies [26,73,104] (Table 7), were suitable
for inclusion in this section of the review. There were
no deaths reported in either arm of the fibrinogen con-
centrate studies included elsewhere in this review. In
the retrospective comparator study, there was no signifi-
cant difference in 30-day mortality between groups. In
the ‘standard therapy’ group, 2 (17%) of 12 patients died
within 30 days of surgery compared with 0 (0%) of 6
patients in the fibrinogen concentrate group, although
this difference was nonsignificant (P > 0.05).
Analysis by logistic regression of data from patients
with acquired acute afibrinogenaemia (due to surgery
and/or trauma) in one retrospective noncomparator
s t u d yi n d i c a t e das t a t i s t i c a l ly significant association
between the higher plasma fibrinogen levels measured
after fibrinogen concentrate administration and 7 day
patient survival [104]. The other study, which reported
the effect of fibrinogen concentrate administration to
trauma patients, observed significantly reduced mortality
compared with the mortality predicted by Trauma
Injury Severity Score (TRISS) and by revised injury
severity classification (RISC) [73].
Length of stay
Fresh frozen plasma
The impact of FFP on LOS for patients in the ICU was
reported in 14 comparator studies [3,24,32,33,39,50,66,
67,69,77,79,81,83,87,105] (Table 8). Of these, over half
reported an increased ICU LOS for patients in the
(high) FFP group compared with controls [39,66,67,
69,77,81,83,105], with two studies reporting ICU stays
were over 50% longer for patients administered FFP
compared with the nontransfused controls [77,105].
Conversely, in one study, a 1:1 FFP:RBC ratio was asso-
ciated with an approximately 50% reduction in ICU
LOS compared with a 1:4 ratio [32,33]. Three studies
Table 7 Evidence for the effect of each intervention on survival
FFP outcomes: survival Fibrinogen concentrate outcomes:
survival
Type of study Improvement No difference Reduction Improvement No
difference
Reduction
RCT - - 1 (1 to 32
days) [38]
1 (in-hospital)
[78]
-- -
Non RCT or prospective comparator - 1 (in-hospital)
[87]
1 (in-hospital)
[77]
-
- -
Retrospective comparator 2 (6 hours) [68,81]
3 (24 hours)
[4,67,81]
7 (30 days)
[3,4,28,39,42,69,81]
1 (90 days) [69]
7 (in-hospital)
[31-34,67,68,86,90,91]
4 (30 days)
[66,84,85,93]
1 (36 months)
[40]
6 (in-hospital)
[31,67,76,79,83,89]
1 (30 days)
[92]
1 (1 year) [82]
1 (10 years)
[88]
2 (in-hospital)
[75,80]
- 1 (30
days) [26]
-
Controlled and/or comparator study outcomes, n
(percentage of all outcomes within intervention
group)
20 (50%) 12 (30%) 8 (20%) 0 1 (100%) 0
Prospective noncomparator 1 (24 hours) [97] - 1 (in-hospital)
[95]
-- -
Retrospective noncomparator 2* (in-hospital)
[99,103]
1 (6 months)
[101]
1 (1 year) [102]
1 (68 months)
[100]
2* (in-hospital)
[96,103]
1 (at 6
months) [101]
2 (in-hospital)
[94,98]
1 (7 days)
[104]
1 (in-hospital)
[73]
--
Case report - - - - - -
Study outcomes, n (percentage of outcomes
within intervention group)
23 (44%) 17 (33%) 12 (23%) 2 (67%) 1 (33%) 0
FFP = fresh frozen plasma; RCT = randomised, controlled trial; - = no data. *Primary analysis excluding early deaths < 48 hours) revealed no association with FFP
administration and survival. Secondary analysis including all patients revealed an association with decreased mortality [103].
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Page 13 of 25found no difference in ICU LOS between the group that
received FFP and a control group that did not
[24,50,79].
Eleven comparator studies reported the effect of FFP
on patients’ hospital LOS [3,24,39,40,66,67,69,77,
79,81,87], with only one reporting a benefit for FFP [24]
(Table 8). Of the three retrospective noncomparator stu-
dies involving FFP, administration was significantly asso-
ciated with an increased or prolonged ICU stay in two
[98,106], but it was not correlated with LOS in the third
[107]. Hospital LOS was reported in one noncomparator
study in which surgical patients were analysed. That
study found that, as with ICU LOS, FFP use was not
correlated with hospital LOS [107].
Fibrinogen concentrate
All three fibrinogen concentrate studies reporting LOS
showed significant reductions in the time spent in the
ICU of 11 hours [55], 78 hours [26] and 36 hours [56]
for patients in the intervention group compared with
those in the control (FFP) group. Hospital LOS was also
reported in these three studies. One observed a signifi-
cantly reduced hospital LOS for patients in the fibrino-
gen concentrate group compared with the control group
(21 days versus 32 days, respectively) [56]. The other
two studies found no difference in hospital LOS
between patients in the intervention and control groups
[26,55].
Plasma fibrinogen levels
Fresh frozen plasma
Eleven FFP comparator studies reported plasma fibrino-
gen levels pre- and postadministration or in relation to
a control [22,23,30,38,41,43,44,49,64,108,109] (Table 9).
It is difficult to compare most of the results directly
because they differ widely in the way in which they were
reported. For instance, some studies compared plasma
fibrinogen levels pre- and postadministration, whereas
others compared the difference in levels between groups
at certain time points. To further complicate matters,
many comparisons were made between groups of
patients receiving different doses or formulations of FFP
and did not compare the effect of FFP against a non
plasma product. A positive effect was seen for the FFP
group in five studies [23,30,38,41,43] whereas the con-
trol group had higher levels in two [44,108].
Four studies assessed the effect of FFP versus a non
blood product. Two found significantly higher plasma
fibrinogen levels postadministration in the FFP group
than in the control group [23,41]. Intraoperative plasma
fibrinogen levels were maintained at the preoperative
level of 2.0 g/L in the FFP group compared with a
decline to an intraoperative value of 1.3 g/L in the albu-
min group in the study involving infants undergoing
craniofacial surgery [23]. In the study of adults under-
going CV surgery, plasma fibrinogen levels fell from a
Table 8 Evidence for the effect of each intervention on ICU and/or hospital length of stay
FFP outcomes: ICU and/or hospital length of
stay
Fibrinogen concentrate
outcomes:
ICU and/or hospital length of
stay
Type of study Reduced No
difference
Increased Reduced No
difference
Increased
RCT - 1 (ICU) [50] - 1 (ICU)
[56]
1
(hospital)
[56]
--
Non RCT or prospective comparator 1
(hospital)
[24]
2 (ICU)
[24,87]
1 (hospital)
[87]
1 (ICU) [77]
1 (hospital) [77]
1 (ICU)
[55]
1
(hospital)
[55]
-
Retrospective comparator 1 (ICU)
[32,33]
2 (ICU) [3,79]
5 (hospital)
[3,39,40,66,79]
7 (ICU)
[39,66,67,69,81,83,105]
*
3 (hospital) [67,69,81]
1 (ICU)
[26]
1
(hospital)
[26]
-
Controlled and/or comparator study outcomes, n (percentage
of all outcomes within intervention group)
2 (8%) 11 (44%) 12 (48%) 4 (67%) 2 (33%) 0
Prospective noncomparator - - - - - -
Retrospective noncomparator - 1 (ICU) [107]
1 (hospital)
[107]
2 (ICU) [98,106] - - -
Case report - - - - - -
Study outcomes, n (percentage of outcomes within
intervention group)
2 (7%) 13 (45%) 14 (48%) 4 (67%) 2 (33%) 0
FFP = fresh frozen plasma; RCT = randomised, controlled trial; - = no data. *For Oberkofler 2010 [83], this represented an increased risk of ICU stay > 10 days.
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Page 14 of 25baseline value of 2.7 g/L to a postadministration value of
1.8 g/L in the FFP group compared with a fall from 2.9
g/L to 1.3 g/L in the HES group, at which point plasma
fibrinogen levels were significantly higher in the FFP
group than in the control group [41]. A third study
reported significantly reduced levels from baseline values
throughout the operative period, with no significant dif-
ferences between the two study groups at any point
despite the administration of 600 ml of FFP to one
group [49]. The fourth study reported significantly lower
plasma fibrinogen levels compared with baseline in the
FFP group, but not in the control group [108].
Chowdhury and colleagues [109] reported the effect
on plasma fibrinogen levels of two different doses of
FFP (12.2 ml/kg and 30 ml/kg) in a prospective, obser-
vational study of a consecutive cohort of patients with
haemorrhage in the ICU. The first 10 patients received
the lower dose, and the next 12 patients received the
higher dose. There was no significant difference between
the two groups postadministration, and plasma fibrino-
gen levels were not significantly higher postadministra-
tion than preadministration in either group.
Five noncomparator studies reported the effect of FFP
on plasma fibrinogen levels. Two indicated a benefit
from FFP [53,70], whilst three found that FFP was asso-
ciated with lower plasma fibrinogen levels [51,110,111].
Of note, one study reporting the effect of FFP on plasma
fibrinogen levels in a cohort of paediatric surgery patients
found the volume of FFP was inversely associated with a
postoperative plasma fibrinogen level < 1.0 g/L [70].
Fibrinogen concentrate
Plasma fibrinogen levels following administration of
fibrinogen concentrate were reported in four compara-
tor studies [26,54,55,71] (Table 9). In all studies, plasma
fibrinogen levels were significantly higher postadminis-
tration in the fibrinogen concentrate group than in the
control group (which received FFP in two studies).
Increases in plasma fibrinogen levels postadministration
ranged from 0.6 g/L following a preoperative 2-g pro-
phylactic dose [54] to 2.0 g/L following a mean intrao-
perative dose of 7.8 g [26]. Importantly, plasma
fibrinogen levels were not significantly higher in the
fibrinogen concentrate group than in the control group
at the next assessment point (6 to 24 hours later).
A further 13 noncomparator studies presented data on
the effect of fibrinogen concentrate on plasma fibrino-
gen levels, all of which also showed an increase in
plasma fibrinogen levels after the intervention
[59-62,72-74,104,112-116]. Six retrospective observa-
tional studies showed mean increases in plasma fibrino-
gen levels, ranging from 0.6 g/L after a median dose of
2 g [74] to 1.7 g/L after a mean dose of 6.5 g [72].
Table 9 Evidence for the effect of each intervention on plasma fibrinogen levels
FFP outcomes: plasma fibrinogen levels Fibrinogen concentrate outcomes:
plasma fibrinogen levels
Type of study Increased/higher No difference Decreased/lower Increased/higher No
difference
Decreased/
lower
RCT 2 (vs
preadministration)
[38,43]
1 (vs comparator)
[41]
3 (vs
preadministration/
comparator)
[22,49,64]
1 (vs
preadministration)
[108]
2 (vs comparator)
[54,71]
--
Non RCT or prospective comparator 1 (vs comparator)
[23]
1 (vs
preadministration/
comparator) [109]
1 (vs comparator)
[44]
1 (vs comparator)
[55]
--
Retrospective comparator 1 (vs comparator)
[30]
- - 1 (vs comparator)
[26]
--
Controlled and/or comparator study
outcomes, n (percentage of outcomes
within intervention group)
5 (46%) 4 (36%) 2 (18%) 4 (100%) 0 0
Prospective noncomparator 1 (vs
preadministration)
[53]
-- - - -
Retrospective noncomparator 1 (vs
preadministration)
[70]
- 1 (vs
preadministration)
[110]
6 (vs
preadministration)
[59,72-74,104,115]
--
Case report - - 2 (vs
preadministration)
[51,111]
7 (vs
preadministration)
[60-62,112-114,116]
--
Study outcomes, n (percentage of
outcomes within intervention group)
7 (44%) 4 (25%) 5 (31%) 17 (100%) 0 0
FFP = fresh frozen plasma; RCT = randomised, controlled trial; - = no data.
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Quality of evidence
There is a relative paucity of high-quality evidence
reporting the outcome of administration of FFP in a
perioperative or massive trauma setting, despite the long
period of its usage. Also, few high-quality trials were
identified that reported the outcome of administration
of fibrinogen concentrate perioperatively, and none
assessed the intervention during massive trauma. Con-
trolled trials with robust blinding and randomisation
procedures are the gold standard when assessing the
efficacy and safety of interventions. However, the low
number of RCTs conducted for each intervention may
reflect the difficulties in designing and implementing
such trials in bleeding patients who are in potentially
life-threatening situations.
Despite there being fewer fibrinogen concentrate com-
parator studies than FFP comparator studies (5 versus
52, respectively), the nature of the comparison must
also be considered. Of the FFP comparator studies ana-
lysed, only 38% (20 of 52) compared FFP with no FFP
or with a non blood product (for example, colloid or
crystalloid). Many FFP studies assessed outcomes against
a control group that received a different dosage or for-
mulation of FFP reflecting the widely held assumption
that ‘standard’ FFP is efficacious in these situations. In
contrast, 40% (2 of 5) of fibrinogen concentrate studies
compared the intervention with either no fibrinogen
concentrate or a colloid or crystalloid control, and the
other 60% (3 of 5) compared the use of fibrinogen con-
centrate with FFP. Therefore, the low number of com-
parator trials for fibrinogen concentrate still provided
useful evidence and allowed valuable comparisons to be
made between the intervention and a non blood control,
as well as a direct comparison with FFP. Whilst observa-
tions can be made about the relative efficacies of FFP
and fibrinogen concentrate in the perioperative setting,
it is notable that, despite a number of noncomparator
studies of fibrinogen concentrate in the trauma setting
(with one recent study involving 128 patients), there are
no comparator studies involving the use of fibrinogen
concentrate in patients with haemorrhage due to mas-
sive trauma. This lack of evidence highlights a need for
more research in this area so that the efficacy of fibrino-
gen concentrate can be assessed in this clinical setting.
Potential for bias
The majority of studies included in this review were
observational in nature and as such could be subject to
bias, particularly in studies in which researchers were
looking for associations between outcomes and different
dosages of an intervention. Most of the studies did not
report whether they had performed an assessment of, or
had controlled for, bias when calculating the effect of the
intervention in question. Bias may have occurred by a
number of mechanisms. First, a selection bias may have
been in effect because the most resources were directed
towards the patients deemed most likely to survive. Sec-
ond, in other studies, the less-well patients may have
received more of an intervention because they were more
ill. Third, the studies may have had a survival bias where
patients in the worst condition died too quickly to receive
a high dose of the intervention, so, by default, the
patients with a poor prognosis were preferentially
included in the low-dose groups. In these instances, data
suggesting that the intervention was responsible for a dif-
ference in morbidity and/or mortality between groups
may not be reliable. It is possible that the intervention
group had a prognosis different from that of the compari-
son group regardless of the amount of the intervention
administered, post hoc ergo propter hoc.
The use of fibrinogen concentrate as a haemostatic
intervention in the management of perioperative bleed-
ing is still in its early years. Therefore, in the current lit-
erature, there may be a publication bias towards studies
demonstrating the successful use of a product rather
than those reporting failure.
Efficacy outcomes
Our systematic literature search identified 70 FFP and
21 fibrinogen concentrate publications reporting the
effects of the intervention on a number of outcomes of
interest. However, although 74% of identified FFP stu-
dies had a comparator group, many involved different
doses or formulations of FFP rather than a non FFP
arm. Furthermore, the majority of fibrinogen concen-
trate studies (76%) were of low quality and did not
report the effect of the intervention in relation to a
comparator group. Figure 2 summarises the results of
all studies in our review with a comparator group for
each intervention by reported outcome and also as a
combined total of all outcomes. Figure 2a reinforces the
doubt about the efficacy of FFP, assessed across a range
of outcomes, with no single outcome reflecting a benefit
for FFP in > 50% of extracted measures. When all out-
comes were added together, a benefit of FFP administra-
tion was found in only 28% of measures, only slightly
more than those reporting a negative effect of FFP
(22%). If only those studies comparing FFP with a non
FFP group are considered, the picture is even less con-
vincing, because only 7% of reported outcomes sup-
ported a beneficial effect of FFP (Figure 2c). In contrast,
the evidence for the efficacy of fibrinogen concentrate
was far more consistent, with no negative outcomes
reported for any measure (Figure 2b). Fibrinogen con-
centrate was shown to reduce blood loss, reduce allo-
geneic transfusion requirements, reduce ICU and
hospital LOS and increase plasma fibrinogen levels in
over two-thirds of reported outcomes. In the five
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fibrinogen concentrate over the control. Importantly,
the control was FFP in three of the studies, thus provid-
ing some evidence that fibrinogen concentrate is more
efficacious than FFP across a range of clinical outcomes
in the perioperative setting.
The strongest support for a benefit for FFP derives
from studies reporting survival, where 50% suggested
that FFP (typically at higher FFP:RBC ratios) reduces
mortality; however, FFP was associated with increased
mortality in 20% of studies. In general, studies reporting
an association of higher doses of FFP with improved
survival assessed the effect of FFP:RBC ratios during
massive transfusion. This finding is in agreement with
the meta-analysis performed by Murad and colleagues
[5]. Many studies targeting higher FFP:RBC ratios did so
by increasing the amount of FFP administered in the
early phase of massive haemorrhage. This temporal
aspect of FFP administration was highlighted in a recent
publication which found that patients who received an
early high FFP:RBC ratio were in less severe shock and
less likely to die early from uncontrollable haemorrhage
than were those patients in the low FFP:RBC ratio
group, who never achieved a high ratio [117]. The survi-
val advantage associated with the higher FFP:RBC ratios
currently being lauded in the literature may be due
partly to selection, whereby patients in such studies die
with a low FFP:RBC ratio, not because of al o wr a t i o .
Fibrinogen deficiency manifests early in bleeding
patients. It is possible that an improvement in survival
rates at higher FFP:RBC ratios was due in part to earlier
supplementation of plasma fibrinogen in the resuscita-
tion effort and not to a benefit of FFP per se.T h ef i b r i -
nogen concentrate studies identified were typically
small, with a mean of only 10 patients per arm. Conse-
quently, there were almost no deaths reported in either
group, making a robust assessment of any survival bene-
fit following the administration of fibrinogen concen-
trate (early or late) virtually impossible.
In this review, we examined relevant outcomes of
interest by analysing the literature regarding one of two
interventions: FFP and fibrinogen concentrate. However,
haemostatic support during surgery or massive trauma
is rarely achieved by the administration of one product
alone; therefore, the majority of the studies included in
this review involved the administration of other pro-
ducts, particularly RBC, but also PC, cryoprecipitate,
prothrombin complex concentrate, tranexamic acid,
aprotinin and others. The influence of coadministered
products on the outcomes of interest was not studied in
this review, though the potential for an impact should
be considered when drawing any conclusions regarding
the impact of each intervention on these outcomes, par-
ticularly in studies where cryoprecipitate was adminis-
tered, as this would provide a more concentrated dose
of fibrinogen than FFP alone.
Risk versus benefit
The benefits of any intervention should outweigh the
risks. In this review, we found inconsistent and
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Furthermore, the findings of this review are in line with
other published work, where FFP has particularly been
associated with an increased risk of mortality when used
during nonmassive transfusi o n[ 5 ] .I nt e r m so fr i s k s ,
Murad and colleagues examined the incidence of ALI
and MOF in their meta-analysis [5], in which they
reported that FFP significantly increased the risk of pul-
monary complications (OR = 2.92). Contrary to
researchers in other studies [103,118], however, they
reported a significant reduction in the risk of MOF with
FFP administration (OR = 0.40). Although the risk of
v i r a la n db a c t e r i a lt r a n s m i s s ion by FFP exists, it is very
low. The introduction of nucleic acid screening for
known infectious diseases has led to the transmission of
infectious diseases being rare [119]. Other adverse
events (AEs) are associated with the use of FFP, such as
allergic and haemolytic transfusion reactions, but these
are infrequent ≤ 1 event per 100,000 blood components
issued [6]). Furthermore, several strategies have been
employed successfully to reduce many of the risks asso-
ciated with ‘standard’ FFP, such as the introduction of
different formulations of plasma (for example, SD-FFP
and photochemical treatment FFP, lyophilised and
others), the use of leucocyte-depleted plasma and
restricting the use of FFP from female donors [9]. Half
of all outcomes analysed in this review indicated that
FFP had no effect, positive or negative, and it could be
argued that administration of FFP is worthwhile on the
basis of the possibility that it might be efficacious and at
worst will effect no change in clinical parameters. None-
theless, when the potential risks associated with FFP,
however rare, are considered in the context of the effi-
cacy findings in this study, in which fewer than one-
third of the reported outcomes favoured FFP over the
comparator, the continued use of the product should be
questioned in an approach that weighs risk versus
benefit.
There was consistent evidence that fibrinogen concen-
trate improved the outcomes studied in this review.
More than two-thirds (16 of 23) of all outcomes showed
a benefit of fibrinogen concentrate over any comparator,
notably 72% (13 of 18) of the outcomes were favourable
for fibrinogen concentrate over FFP. Furthermore, no
study reported a negative effect versus a comparator on
any outcome measure included in this review. In terms of
the risks involved with fibrinogen concentrate, there is a
low risk of AEs such as allergic reactions, and, in rare
cases, administration of fibrinogen concentrate has been
associated with thromboembolic events [120,121]. A
number of preclinical studies have provided evidence
supporting the safety and tolerability of fibrinogen con-
centrate, and preclinical models, including one of venous
stasis, have shown no evidence of thrombosis formation
in treated animals, demonstrating the low thrombogenic
potential of the product [120,122-125]. In addition, a
pharmacosurveillance report and systematic review of
thrombotic events in clinical studies (of patients with
both congenital and acquired afibrinogenaemia) showed
no significant safety concerns associated with fibrinogen
concentrate (Haemocomplettan P; CSL Behring, Mar-
burg, Germany) use in perioperative bleeding situations
with regard to thrombogenicity [120]. Over a 22-year
pharmacosurveillance period, nine thrombotic events
possibly related to the administration of fibrinogen con-
centrate were reported (seven of which were in patients
with congenital fibrinogen deficiency) at an incidence of
3.48 per 100,000 treatment episodes. However, further
safety studies employing rigorous methods intended to
detect conditions such as deep vein thrombosis are still
required to confirm the findings from the preclinical and
pharmacosurveillance studies.
Among the trials included in this review
[26,54-63,71-74,104,112-116], there was a low incidence
of the predefined safety outcomes (thrombotic events,
ALI, TACO, infections [bacterial contamination and
viral transmission] and MOF). Furthermore, there was a
low frequency of AEs of any nature in the 17 fibrinogen
concentrate studies in which AEs were reported (Table
10). Of the trials with a comparator group, an AE (post-
operative atrial fibrillation) was reported for 1 of 36
(3%) patients receiving fibrinogen concentrate compared
with 7 of 37 (19%) of patients in the comparator groups
[26,54,55,71]. There were another seven AEs reported in
the noncomparator trials and case reports of 240
patients receiving fibrinogen concentrate (3%)
[57-61,63,72,74,104,112,113,115,116]. Four of the AEs
(all arterial ischaemic events) occurred between 4 and
12 days (median = 7.5 days) after fibrinogen concentrate
administration in postoperative surgical patients who
had massive perioperative haemorrhage and required
more than 12 U of RBC [115]. Of the remaining three
A E s ,o n ec a s eo f‘jitter and snoring respiration’ was
reported by nursing staff, though the patient was judged
to be alert with normal respiration upon the arrival of
the attending physician; one patient complained of
attacks of shivering 24 hours after fibrinogen concen-
trate administration [59]; and one patient who received
massive transfusion of a variety of haemostatic products
had subsequent acute renal failure [116].
This review presents a consistent picture of the effi-
cacy of fibrinogen concentrate and supports the safety
of the product, with a low incidence of thrombotic
events reported in the included studies. However, this
evidence was derived from a small number of studies
with a low number of patients in each arm. Whilst pub-
lished studies support the efficacy and safety of fibrino-
gen concentrate during surgical procedures, more trials
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Patients, N Adverse events*^, n (%)
Study type Indication Fibrinogen
concentrate
Comparator Fibrinogen
concentrate
Comparator Details
RCTs
Cui et al. (2010) [56] CV surgery
(children)
17 14 - - Adverse events not reported
Fenger-Eriksen et al.
(2009) [71]
Surgery
(cystectomy)
10 10 0 0
Karlsson et al. (2009) [54] CV surgery 10 10 0 1 (10%) 1 perioperative myocardial infarction
(comparator group)
Trials with a comparator group
Rahe-Meyer et al.
(2009) [55]
CV surgery 10 5 1 (10%) 1 (20%) 2 postoperative atrial fibrillation (1
fibrinogen concentrate group, 1
comparator group)
Rahe-Meyer et al.
(2009) [26]
CV surgery 6 12 0 5 (42%) 1 postoperative atrial fibrillation
(comparator group)
2 renal failure (2 comparator group)
2 major neurological events (2
comparator group)
Totals (comparator
trials reporting
adverse events)
36 37 1 (3%) 7 (19%)
Noncomparator trials and case reports
Bell et al. (2010) [112] Postpartum
haemorrhage
6- 0-
Böhrer et al. (1999) [57] Liver
transplantation
1- 0-
Brenni et al. (2010) [58] Trauma 1 - 0 -
Farriols Danés et al.
(2008) [104]
Various 69 - 0 -
Fenger-Eriksen et al.
(2008) [59]
Severe
bleeding
43 - 2 (5%) - 1 jitter and snoring respiration
1 shivering (causal relationship to
fibrinogen concentrate administration
could not be excluded in either case)
Glover et al. (2010) [63] Postpartum
haemorrhage
1- 0-
Haas et al. (2008) [113] Surgery
(craniofacial,
paediatric)
9- 0-
Heindl et al. (2005) [116] Surgery (other) 2 - 1 - 1 acute renal failure (case 1)
Innerhofer (2006) [60] Surgery
(lumbar)
1- 0-
Peitsidou et al. (2008) [114] Emergency
caesarean
section and
hysterectomy
1 - - - Adverse events not reported
Schöchl et al. (2010) [61] Massive trauma,
then
laparotomy
1- 0-
Schöchl et al. (2010) [62] Trauma surgery 1 - - - Adverse events not reported
Schöchl et al. (2010) [73] Trauma surgery 128 - - - Adverse events not reported
Solomon et al. (2010) [72] CV surgery 39 - 0 -
Thorarinsdottir et al.
(2010) [74]
Surgery
(various)
37 - 0 -
Weinkove et al. (2008) [115] Various 30 - 4 (13%) - 4 arterial ischaemic events (median
7.5 days (range 4 to 12 days)
following fibrinogen concentrate
administration)
Totals (noncomparator
trials and case
reports reporting
adverse events)
240 - 7 (3%) -
CV = cardiovascular; RCT = randomised, controlled trial; - = no data. *Predefined safety outcomes: thrombotic events, acute lung injury, transfusion-associated
circulatory overload, infections (bacterial contamination and viral transmission) and multiple organ failure.
^excludes deaths.
Kozek-Langenecker et al. Critical Care 2011, 15:R239
http://ccforum.com/content/15/5/R239
Page 19 of 25reporting outcomes from a greater number of patients
are needed to reinforce these findings.
Fresh frozen plasma and fibrinogen concentrate during
surgery and massive trauma
The use of haemostatic products often occurs in
response to a ‘trigger’, and for FFP, historically, this was
based on the percentage of blood volume lost. However,
there are many difficulties inherent in estimating the
volume of blood lost in a patient with a life-threatening
massive haemorrhage, for whom resuscitation efforts
may continue for some time. Though primarily used
during massive trauma bleeding, a ratio-based approach,
often integrated into a massive transfusion protocol
which aims to coordinate the activities of the various
necessary departments and personnel, is steadily repla-
c i n gt h ev o l u m eo fb l o o dl o s sa st h et r i g g e rf o rF F P
administration. This approach appears simple and prac-
tical, though concerns remain, not the least of which is
that the optimum FFP:RBC ratio has yet to be deter-
mined [126], an observation highlighted in recent evi-
dence-based guidelines [127]. In addition to uncertainty
over the optimum FFP:RBC ratio, there are a number of
logistical considerations, such as potential issues with
the availability of thawed FFP, the waste that could be
created by immediately thawing large quantities of FFP
(because of the short shelf-life of thawed FFP) and the
need for ABO-compatible plasma early on. Interestingly,
three studies prompt questions regarding the survival
benefits reported for increased FFP:RBC ratios in mas-
sive trauma patients. Snyder and colleagues [89] sug-
gested that the reduction in mortality reported in many
studies of this type is due to survival bias brought about
by the exclusion from the analyses of patients who died
during the early phase of the study. To test this hypoth-
esis, they performed an analysis adjusted for survival
bias and found that an FFP:RBC ratio ≥ 1:2 no longer
had any effect on in-hospital mortality rates compared
with < 1:2. Furthermore, both Riskin and colleagues [85]
and Gunter and colleagues [28] found a significant
improvement in survival after implementation of a mas-
sive transfusion protocol despite unchanged FFP:RBC
ratios. This suggests that simply increasing the amount
of FFP administered during a massive transfusion is not
the key factor in improving survival and that other fac-
tors inherent in a transfusion protocol also have a sub-
stantial impact. The survival benefit of FFP may be due
more to the focus on ‘haemostasis’ and the timely deliv-
ery of blood products rather than to the increase in
FFP, which was reinforced in a recent review of the
impact of the introduction of goal-directed haemostatic
resuscitation on surgical and trauma patients [128].
When a ratio-based approach is not considered appro-
priate, such as during routine surgical procedures, a
laboratory test-based approach is often employed to guide
the administration of FFP on the basis of the prothrombin
time and International Normalised Ratio. However, only
the initiation phase of haemostasis is monitored by con-
ventional coagulation tests. Screening may not indicate
abnormalities, such as the presence of critically low fibri-
nogen levels, if the coagulopathy occurs in the amplifica-
tion, propagation or stabilisation phase. The change in
plasma fibrinogen levels reported in relevant studies in
response to different doses of FFP and fibrinogen concen-
trate indicate that a good response was achieved in all stu-
dies in which fibrinogen concentrate was used, with 2 to 4
g typically raising plasma fibrinogen levels by around 1 g/
L [26,54,55, 59,71,72,104,113,115]. The increases in levels
were generally more variable and less predictable for FFP
[22,23,30,38,41,49,53,64,108-110]. According to recent
measurements, because 1 L of FFP provides an average of
2.0 g of fibrinogen [16] and the same amount of fibrinogen
can be found in just 100 ml of fibrinogen concentrate [17],
the use of fibrinogen concentrate over FFP for substitution
of fibrinogen may be more favourable. This reduced infu-
sion volume may help avoid dilutional coagulopathy and
the risk of volume overload associated with FFP use in
patients with nonmassive bleeding. Conversely, in situa-
tions where a patient has experienced massive blood loss,
the greater infusion volume of FFP may better restore
some of the lost volume (though FFP should never be
used solely as a volume expander [9,119]).
A goal-directed approach using low fibrinogen levels as
a trigger for intervention could improve outcomes. The
efficacy of fibrinogen concentrate to improve haemostasis
has been demonstrated in a number of in vitro and animal
models of haemodilution and severe bleeding
[120,122-125,129,130]. These efficacious findings in precli-
nical studies are supported by the safety record of fibrino-
gen concentrate, such as the low thrombogenic potential
demonstrated in animal models [120,124,125], and that
reported in published trials. In our experience, fibrinogen
concentrate has some clear advantages over FFP. The pre-
paration method carries a reduced risk of immunological
side effects, reduced risk of viral transmission, reduced
transfusion volume and a known factor content [20]. In
addition to the low risk of the product, its low volume
facilitates faster infusion times. Furthermore, rapid admin-
istration is possible because there is no need to blood-
type, thaw or warm fibrinogen concentrate.
Conclusions
The evidence for the efficacy of FFP in our review was
inconsistent across all assessed outcomes. The weight of
the evidence does not appear to support the clinical
effectiveness of FFP in many situations, and even sug-
g e s t st h a ti tc a nb ed e t r i m e n t a l .T h ee v i d e n c ew a st y p i -
cally not of high quality, and, combined with
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conclusions about the benefits of FFP in the periopera-
tive and/or massive trauma setting is difficult. In con-
trast, despite a low number of studies reporting
outcomes associated with the perioperative administra-
tion of fibrinogen concentrate, there was a much more
consistent message showing a benefit of fibrinogen con-
centrate over both FFP and crystalloid and colloid on a
number of outcome measures, including reduction of
blood loss and allogeneic transfusions. Perioperatively,
the use of fibrinogen concentrate in an early goal-direc-
ted coagulation management strategy may be preferable
to FFP in terms of clinical effectiveness. However, there
is currently insufficient evidence in the literature to
draw any definitive conclusions. More high-quality pro-
spective studies, particularly studies directly comparing
fibrinogen concentrate with FFP, are required.
Key messages
◆ There is a relative paucity of high-quality prospec-
tive studies reporting the outcome of FFP adminis-
tration in a perioperative or massive trauma setting,
despite having been in use for many years.
◆ There is inconsistent and contradictory evidence
concerning the efficacy of FFP. No single outcome
has shown a benefit of FFP in > 50% of extracted
measures.
◆ The use of fibrinogen concentrate as a haemo-
static intervention in the management of periopera-
tive bleeding is still in its early years, which is
reflected by the low number of published studies
that we identified.
◆ Evidence for the efficacy of fibrinogen concentrate
was consistent, with no negative outcome reported
for any measure.
◆ There appears to be some promise in the use of
fibrinogen concentrate instead of FFP for the treat-
ment of acquired bleeding, although there is insuffi-
cient evidence currently available in the literature to
draw any definitive conclusions. More high-quality
prospective studies are needed, particularly studies
directly comparing fibrinogen concentrate with FFP.
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